join us
CN
Home page
About Us
Profile
Affiliates/Subsidiaries
Development History
Quality Management
Contact Us
Legal Statement
Privacy Statement
Adverse Reaction Report
Science and Technology
R&D platform
R&D pipeline
Therapeutic Field
International Business
APIs
Finished Products
Medical device
Download product list
Contact
News Center
News & Trends
Public information
News & Trends
28
2025-05
Salubris Obtains Exclusive License for Small Interfering RNA Drug "GW906"
27
2025-05
Blockbuster! China's First Domestically Developed ARNI Hypertension Drug Xin Chao Tuo (Sacubitril Alisartan Calcium Tablets) Approved for Market
30
2025-04
Salubris' Novel Hypertension Drug SAL0140 Gained Clinical Trial Approval
17
2025-04
Salubris' PCSK9 base-editing drug YOLT-101 has received NMPA acceptance for its clinical trial application
14
2025-02
SAL0140 Clinical Trial Application Accepted by NMPA, Potential Breakthrough in Hypertension Treatment
20
2025-01
Announcement of the Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure
目前在第
4
页,
共有
14
页,
共有
82
条记录
第一页
上一页
2
3
4
5
6
下一页
最后一页
跳转到
页